PVI
CBIO

Pine Valley Investments’s Crescent Biopharma CBIO Stock Holding History

Pine Valley Investments’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-125
Closed -$2.63K – 580
2025
Q1 		$2.63K Hold
125
– – ﹤0.01% 559
2024
Q4 		$3.12K Hold
125
– – ﹤0.01% 517
2024
Q3 		$2.12K Buy
+125
New +$2.62K ﹤0.01% 516
2024
Q2 		– Sell
-125
Closed -$37.6K – 502
2024
Q1 		$37.6K Hold
125
– – ﹤0.01% 478
2023
Q4 		$29.5K Hold
125
– – ﹤0.01% 484
2023
Q3 		$18.8K Hold
125
– – ﹤0.01% 462
2023
Q2 		$21.8K Hold
125
– – ﹤0.01% 418
2023
Q1 		$19K Buy
+125
New +$28.1K ﹤0.01% 303

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Pine Valley Investments's CBIO Position: Q2 2025 in Review

Pine Valley Investments sold out of Crescent Biopharma (CBIO) in Q2 2025, closing a stake of 125 shares — an estimated $2.63K sold.

Pine Valley Investments first reported a position in CBIO in Q1 2023 and held it in 8 quarters. The position peaked at $37.6K in Q1 2024. 30 funds tracked by Wall St. Rank hold CBIO as of Q2 2025.

  • Pine Valley Investments reported no remaining Crescent Biopharma position as of Q2 2025 after selling out during the quarter.
  • Pine Valley Investments sold 125 Crescent Biopharma shares in Q2 2025, an estimated $2.63K.
  • Pine Valley Investments first reported a position in Crescent Biopharma in Q1 2023 and held it in 8 quarters.
  • Pine Valley Investments's Crescent Biopharma position peaked at $37.6K in Q1 2024.
  • 30 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2025.

Based on Pine Valley Investments's 13F filing for Q2 2025, filed 17 Feb 2026.